Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage

AIDS Research and Human Retroviruses

Volumn 15, Issue 8, 1999, Pages 731-743

  Verrier, Florence ^a   Borman, Andrew M ^a   Brand, Denys ^b   Girard, Marc ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; T LYMPHOCYTE RECEPTOR;

AMINO ACID SUBSTITUTION; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECEPTOR AFFINITY; RECEPTOR BINDING; STRAIN DIFFERENCE; SYNCYTIUM; T LYMPHOCYTE ACTIVATION; VIRUS CELL INTERACTION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; GIANT CELLS; HELA CELLS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033586993     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310827     Document Type: Article

References (80)

1. Verrier FC, Charneau P, Altmeyer R, Laurent S, Borman AM, and Girard M: Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate. Proc Natl Acad Sci USA 1997;94:9326-9331.
2. Earl PL, Moss B, and Doms RW: Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol 1991;65:2047-2055.
3. Willey RL, Bonifacino JS, Potts BJ, Martin MA, and Klausner RD: Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci USA 1988;85:9580-9584.
4. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, and Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (London) 1984;312:763-767.
5. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, and Montagnier L: T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (London) 1984;312:767-768.
6. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, and Berger EA: CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958.
7. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, and Sodroski J: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HTV-1 isolates. Cell 1996;85:1135-1148.
8. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, and Landau NR: Identification of a major co-receptor for primary isolates of HIV-I. Nature (London) 1996;381:661-666.
9. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, and Doms RW: A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85: 1149-1158.
10. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, and Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (London) 1996;381:667-673.
11. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
12. Loetscher M, Geiser T, O'Reilly T, Zwahlen R, Baggiolini M, and Moser B: Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes. J Biol Chem 1994;269:232-237.
13. Lasky LA, Nakamura G, Smith DH, Fennie C, Shimasaki C, Patzer E, Berman P, Gregory T, and Capon DJ: Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 1987;50:975-985.
14. Sattentau QJ and Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991;174:407-415.
15. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, and Moore JP: CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature (London) 1996;384:184-187.
16. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, and Sodroski J: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (London) 1996;384:179-183.
17. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, and Sodroski J: Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995;69:5723-5733.
18. Chan DC, Fass D, Berger JM, and Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-273.
19. Weissenhorn W, Wharton SA, Calder LJ, Earl PL, Moss B, Aliprandis E, Skehel JJ, and Wiley DC: The ectodomain of HIV-1 Env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J 1996;15:1507-1514.
20. Wild C, Dubay JW, Greenwell T, Baird T Jr, Oas TG, McDanal C, Hunter E, and Matthews T: Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci USA 1994;91:12676-12680.
21. Lapham CK, Ouyang J, Chandrasekhar B, Nguyen NY, Dimitrov DS, and Golding H: Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 1996;274:602-605.
22. Fenyö EM, Albert J, and Asjö B: Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS 1989;3:S5-12.
23. Simmons G, Wilkinson D, Reeves JD, Dittmar MT, Beddows S, Weber J, Carnegie G, Desselberger U, Gray PW, Weiss RA, and Clapham PR: Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol 1996;70:8355-8360.
24. Dittmar MT, McKnight A, Simmons G, Clapham PR, Weiss RA, and Simmonds P: HIV-1 tropism and co-receptor use. Nature (London) 1997;385:495-496.
25. Deng HK, Unutmaz D, KewalRamani VN, and Littman DR: Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature (London) 1997;388:296-300.
26. Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, and Farber JM: STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 1997;185:2015-2023.
27. Farzan M, Choe H, Martin K, Marcon L, Hofmann W, Karlsson G, Sun Y, Barrett P, Marchand N, Sullivan N, Gerard N, Gerard C, and Sodroski J: Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med 1997;186:405-411.
28. Berson JF, Long D, Doranz BJ, Rucker J, Jirik FR, and Doms RW: A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996;70:6288-6295.
29. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, and Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
30. Cheng-Mayer C, Liu R, Landau NR, and Stamatatos L: Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J Virol 1997;71:1657-1661.
31. Goudsmit J: The role of viral diversity in HIV pathogenesis. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:S15-19.
32. Koot M, van't Wout AB, Kootstra NA, de Goede RE, Tersmette M, and Schuitemaker H: Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 1996;173:349-354.
33. Richman DD and Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-974.
34. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, and Tersmette M: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66:1354-1360.
35. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
36. Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F, and Tersmette M: Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991;65:356-363.
37. Valentin A, Albert J, Fenyö EM, and Asjö B: Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates. J Virol 1994; 68:6684-6689.
38. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, and Ho DD: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993;261:1179-1181.
39. Connor RI and Ho DD: Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 1994;68:4400-4408.
40. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyö EM, and Lusso P: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nature Med 1997;3:1259-1265.
41. Glushakova S, Baibakov B, Zimmerberg J, and Margolis LB: Experimental HIV infection of human lymphoid tissue: Correlation of CD4+ T cell depletion and virus syncytium-inducing/non-syncytium-inducing phenotype in histocultures inoculated with laboratory strains and patient isolates of HIV type 1. AIDS Res Hum Retroviruses 1997;13:461-471.
42. Andeweg AC, Leeflang P, Osterhaus AD, and Bosch ML: Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol 1993;67:3232-3239.
43. De Jong JJ, De Ronde A, Keulen W, Tersmette M, and Goudsmit J: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis of single amino acid substitution. J Virol 1992;66:6777-6680.
44. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, and Schuitemaker H: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
45. Groenink M, Fouchier RA, Broersen S, Baker CH, Koot M, van't Wout AB, Huisman HG, Miedema F, Tersmette M, and Schuitemaker H: Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 1993;260:1513-1516.
46. Hwang SS, Boyle TJ, Lyerly HK, and Cullen BR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991:253:71-74.
47. de Jong JJ, Goudsmit J, Keulen W, Klaver B, Krone W, Tersmette M, and de Ronde A: Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 1992;66:757-765.
48. Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P, Pal R, Gallo RC, and Reitz MS Jr: Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 1995:69:3712-3720.
49. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, and Lusso P: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nature Med 1996;2:1244-1247.
50. Koito A, Stamatatos L, and Cheng-Mayer C: Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. Virology 1995;206:878-884.
51. Cornelissen M, Hogervorst E, Zorgdrager F, Hartman S, and Goudsmit J: Maintenance of syncytium-inducing phenotype of HIV type 1 is associated with positively charged residues in the HIV type 1 gp120 V2 domain without fixed positions, elongation, or relocated N-linked glycosylation sites. AIDS Res Hum Retroviruses 1995;11:1169-1175.
52. Sullivan N, Thali M, Furman C, Ho DD, and Sodroski J: Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J Virol 1993;67:3674-3679.
53. Kuiken CL, de Jong JJ, Baan E, Keulen W, Tersmette M, and Goudsmit J: Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol 1992; 66:4622-4627.
54. Distler O, McQueen PW, Tsang ML, Evans LA, Hurren L, Byrne C, Penny R, Cooper DA, and Delaney SF: Primary structure of the V3 region of gp120 from sequential human immunodeficiency virus type 1 isolates obtained from patients from the time of sero-conversion. J Infect Dis 1995;172:1384-1387.
55. Fouchier RA, Brouwer M, Broersen SM, and Schuitemaker H: Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol 1995;33:906-911.
56. Seillier-Moiseiwitsch F, Margolin BH, and Swanstrom R: Genetic variability of the human immunodeficiency virus: Statistical and biological issues. Annu Rev Genet 1994;28:559-596.
57. Bhattacharyya D, Brooks BR, and Challahan L: Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype. AIDS Res Hum Retroviruses 1996;12:83-90.
58. Kunkel TA: Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci USA 1985;82:488-492.
59. Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, and Clavel F: HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994;241:651-662.
60. Speck RF, Wehrly K, Platt EJ, Atchison RE, Charo IF, Rabat D, Chesebro B, and Goldsmith MA: Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 1997;71:7136-7139.
61. Kim FM, Kolson DL, Balliet JW, Srinivasan A, and Collman RG: V3-independent determinants of macrophage tropism in a primary human immunodeficiency virus type 1 isolate. J Virol 1995;69:1755-1761.
62. Shioda T, Levy JA, and Cheng-Mayer C: Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (London) 1991;349:167-169.
63. Koito A, Harrowe G, Levy JA, and Cheng-Mayer C: Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol 1994;68:2253-2259.
64. Smyth RJ, Yi Y, Singh A, and Collman RG: Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate. J Virol 1998;72:4478-4484.
65. Hill CM, Deng H, Unutmaz D, Kewalramani VN, Bastiani L, Gorny MK, Zolla-Pazner S, and Littman DR: Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J Virol 1997;71:6269-6304.
66. Bandres JC, Wang QF, O'Leary J, Baleaux F, Amara A, Hoxie JA, Zolla-Pazner S, and Gorny MK: Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. J Virol 1998;72:2500-2504.
67. Sakaida H, Hori T, Yonezawa A, Sato A, Isaka Y, Yoshie O, Hattori T, and Uchiyama T: T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection. J Virol 1998;12:9763-9770.
68. Korber BT, MacInnes K, Smith RF, and Myers G: Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol 1994;68: 6730-6744.
69. Myers G: Tenth anniversary perspectives on AIDS. HIV: Between past and future. AIDS Res Hum Retroviruses 1994;10:1317-1324.
70. Stamatatos L and Cheng-Mayer C: Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J Virol 1995;69:6191-6198.
71. Wang WK, Dudek T, Zhao YJ, Brumblay HG, Essex M, and Lee TH: CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120. Proc Natl Acad Sci USA 1998;95:5740-5745.
72. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, and Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (London) 1998;393:648-659.
73. Wyatt R and Sodroski J: The HIV-1 envelope glycoproteins: Fusogenes, antigens and immunogens. Science 1998;280:1884-1888.
74. Shioda T, Oka S, Xin X, Liu H, Harukuni R, Kurotani A, Fukushima M, Hasan MK, Shiino T, Takebe Y, Iwamoto A, and Nagai Y: In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: Association of V2 extension with slow disease progression. J Virol 1997;71:4871-4881.
75. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, and O'Brien WA: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997;186:1395-1400.
76. Berger EA: HIV entry and tropism: The chemokine receptor connection. AIDS 1997;11:S3-16.
77. Bieniasz PD, Fridell RA, Aramori I, Ferguson SS, Caron MG, and Cullen BR: HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor. EMBO J 1997;16:2599-2609.
78. Picard L, Simmons G, Power CA, Meyer A, Weiss RA, and Clapham PR: Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol 1997;71:5003-5011.
79. Hebert CA, Vitangcol RV, and Baker JB: Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J Biol Chem 1991;266:18989-18994.
80. Leong SR, Kabakoff RC, and Hebert, CA: Complete mutagenesis of the extracellular domain of interleukin-8 (IL-8) type A receptor identifies charged residues mediating IL-8 binding and signal transduction. J Biol Chem 1994;269:19343-19348.